Secarna Pharmaceuticals and Scenic Biotech Join Forces to Develop Novel Oligonucleotide Therapies for Severe Genetic Diseases

Secarna Pharmaceuticals GmbH & Co. KG, a biotechnology company focused on next-generation oligonucleotide therapeutics, has announced a strategic collaboration with Scenic Biotech B.V., known for its work in modifier therapies for severe genetic disorders.

The agreement involves the joint discovery and co-development of oligonucleotide therapies targeting a novel disease mechanism identified and validated using Scenic’s proprietary Cell-Seq platform.

Under the partnership, Secarna will lead oligonucleotide discovery efforts using its AI-powered OligoCreator platform, which accelerates the drug discovery process from target selection to therapeutic candidate development. OligoCreator’s technology enables rapid identification and characterization of potentially safe and effective oligonucleotide candidates.

Meanwhile, Scenic Biotech will contribute its deep expertise in target and disease biology, leveraging its Cell-Seq technology to uncover genetic modifiers that can transform disease outcomes.

“We are really excited to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases,” said Konstantin Petropoulos, PhD, CEO of Secarna Pharmaceuticals. “Our complementary technologies—Scenic’s Cell-Seq and Secarna’s OligoCreator—create a powerful framework for discovering breakthrough treatments for patients with currently untreatable conditions.”

This collaboration reflects both companies’ shared commitment to advancing precision medicine and creating transformative therapies for patients with unmet medical needs.

About Secarna Pharmaceuticals

Secarna Pharmaceuticals is a biopharmaceutical company redefining the discovery and development of best-in-class oligonucleotide therapeutics. Its mission is to deliver disease-modifying therapies that address conditions beyond the reach of existing treatment modalities.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!